

Donald W Cockcroft

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10792740/publications.pdf>

Version: 2024-02-01

118
papers

3,681
citations

147726

31
h-index

133188

59
g-index

122
all docs

122
docs citations

122
times ranked

2953
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms of airway hyperresponsiveness. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 118, 551-559.	1.5	354
2	ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. <i>European Respiratory Journal</i> , 2017, 49, 1601526.	3.1	237
3	Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1007-1014.	2.5	215
4	Direct Challenge Tests. <i>Chest</i> , 2010, 138, 18S-24S.	0.4	181
5	Inhaled Corticosteroids Do Not Prevent the Development of Tolerance to the Bronchoprotective Effect of Salmeterol. <i>Chest</i> , 1996, 109, 953-956.	0.4	161
6	Rapid Onset of Tolerance to the Bronchoprotective Effect of Salmeterol. <i>Chest</i> , 1995, 108, 1235-1239.	0.4	160
7	Antisense Therapy against CCR3 and the Common Beta Chain Attenuates Allergen-induced Eosinophilic Responses. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 177, 952-958.	2.5	139
8	Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1051-1059.	1.5	122
9	Nonspecific interstitial pneumonia and usual interstitial pneumonia with mutation in surfactant protein C in familial pulmonary fibrosis. <i>Modern Pathology</i> , 2004, 17, 973-980.	2.9	96
10	The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 331-338.	1.5	94
11	ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. <i>European Respiratory Journal</i> , 2018, 52, 1801033.	3.1	94
12	Methacholine test and the diagnosis of asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 556.	1.5	85
13	Lung function and respiratory symptoms in a randomized smoking cessation trial of electronic cigarettes. <i>Clinical Science</i> , 2016, 130, 1929-1937.	1.8	83
14	Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 106, 57-64.	1.5	80
15	Methacholine Challenge. <i>Chest</i> , 2005, 127, 839-844.	0.4	79
16	The bronchoprotective effect of inhaling methacholine by using total lung capacity inspirations has a marked influence on the interpretation of the test result. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1244-1248.	1.5	79
17	Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: Dose response. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 47-52.	1.5	74
18	ULTIMOB RANCHIAL ORIGIN OF CALCITONIN. HYPOCALCEMIC EFFECT OF EXTRACTS FROM CHICKEN GLANDS. <i>Canadian Journal of Physiology and Pharmacology</i> , 1967, 45, 1095-1099.	0.7	70

#	ARTICLE	IF	CITATIONS
19	Difference Between Dosimeter and Tidal Breathing Methacholine Challenge. <i>Chest</i> , 2005, 128, 4018-4023.	0.4	62
20	Importance of Evaporative Water Losses During Standardized Nebulized Inhalation Provocation Tests. <i>Chest</i> , 1989, 96, 505-508.	0.4	58
21	Methacholine Challenge. <i>Chest</i> , 2001, 120, 1857-1860.	0.4	52
22	Tolerance to the bronchoprotective effect of β_2 -agonists: Comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 103, 1049-1053.	1.5	47
23	Bronchoprovocation Methods: Direct Challenges. <i>Clinical Reviews in Allergy and Immunology</i> , 2003, 24, 19-26.	2.9	46
24	Tolerance to the Bronchoprotective Effect of Salmeterol 12 Hours After Starting Twice Daily Treatment. <i>Annals of Allergy, Asthma and Immunology</i> , 1998, 80, 31-34.	0.5	45
25	ELR-CXC Chemokine Receptor Antagonism Targets Inflammatory Responses at Multiple Levels. <i>Journal of Immunology</i> , 2009, 182, 3213-3222.	0.4	44
26	Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β_2 -agonist, in patients with mild asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 1217-1221.	1.5	44
27	Comparison of 3 different doses of budesonide and placebo on the early asthmatic response to inhaled allergen. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 363-367.	1.5	43
28	Methacholine PC20 Extrapolation. <i>Chest</i> , 1998, 114, 1796-1797.	0.4	43
29	Dosimeter methacholine challenge: Comparison of maximal versus submaximal inhalations. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 517-519.	1.5	43
30	Airway Responsiveness to Inhaled Histamine in Chronic Obstructive Airways Disease. <i>Chest</i> , 1988, 94, 457-461.	0.4	40
31	Constrictive Bronchiolitis and Ulcerative Colitis. <i>Canadian Respiratory Journal</i> , 1999, 6, 197-200.	0.8	34
32	Diagnostic and therapeutic value of airway challenges in asthma. <i>Current Allergy and Asthma Reports</i> , 2009, 9, 247-253.	2.4	31
33	Understanding Allergic Asthma from Allergen Inhalation Tests. <i>Canadian Respiratory Journal</i> , 2007, 14, 414-418.	0.8	27
34	International consensus on lung function testing during the COVID-19 pandemic and beyond. <i>ERJ Open Research</i> , 2022, 8, 00602-2021.	1.1	27
35	Environmental Causes of Asthma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 012-018.	0.8	23
36	Formoterol Thrice Weekly Does Not Result in the Development of Tolerance to Bronchoprotection. <i>Canadian Respiratory Journal</i> , 2003, 10, 23-26.	0.8	22

#	ARTICLE	IF	CITATIONS
37	Correlation between airway inflammation and loss of deep-inhalation bronchoprotection in asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 101, 413-418.	0.5	21
38	Past, present and future uses of methacholine testing. <i>Expert Review of Respiratory Medicine</i> , 2012, 6, 321-329.	1.0	20
39	Prevalence and determinants of atopy and allergic diseases among school-age children in rural Saskatchewan, Canada. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 113, 430-439.	0.5	20
40	Thunderstorm asthma: An allergen-induced early asthmatic response. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 120-123.	0.5	20
41	Calculation of Provocative Concentration Causing a 20% Fall in FEV1. <i>Chest</i> , 2000, 117, 881-883.	0.4	19
42	Regular Inhaled Salbutamol. <i>Chest</i> , 2001, 119, 370-375.	0.4	19
43	Deep Inspiration Avoidance and Methacholine Response in Normal Subjects and Patients With Asthma. <i>Chest</i> , 2005, 127, 135-142.	0.4	19
44	The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study. <i>Respiratory Research</i> , 2017, 18, 146.	1.4	19
45	Methacholine challenge testing: comparative pharmacology. <i>Journal of Asthma and Allergy</i> , 2018, Volume 11, 89-99.	1.5	19
46	Duration of bronchoprotection of the long-acting muscarinic antagonists tiotropium & glycopyrronium against methacholine-induced bronchoconstriction in mild asthmatics. <i>Respiratory Medicine</i> , 2016, 118, 96-101.	1.3	18
47	Comparison of the Provocative Concentration of Methacholine Causing a 20% Fall in FEV ₁ between the AeroEclipse II Breath-Actuated Nebulizer and the Wright Nebulizer in Adult Subjects with Asthma. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1039-1043.	1.5	17
48	Salmeterol and Airway Response to Allergen. <i>Canadian Respiratory Journal</i> , 1997, 4, 37-40.	0.8	16
49	Dose versus concentration of methacholine. <i>Annals of Allergy, Asthma and Immunology</i> , 1999, 83, 229-230.	0.5	16
50	Are inhaled longacting β_2 agonists detrimental to asthma?. <i>Lancet Respiratory Medicine</i> , 2013, 1, 339-346.	5.2	14
51	Epidemic thunderstorm asthma. <i>Lancet Planetary Health</i> , 2018, 2, e236-e237.	5.1	14
52	Allergen provocation tests in respiratory research: building on 50 years of experience. <i>European Respiratory Journal</i> , 2022, 60, 2102782.	3.1	14
53	Inhaled β_2 -agonists and airway responses to allergen. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, S96-S99.	1.5	13
54	Extrapolation of Methacholine PC20. <i>Chest</i> , 2002, 122, 1499-1500.	0.4	13

#	ARTICLE	IF	CITATIONS
55	Methacholine Challenge Testing. Chest, 2017, 152, 1251-1257.	0.4	13
56	Familial Interstitial Pulmonary Fibrosis: A Large Family with Atypical Clinical Features. Canadian Respiratory Journal, 2010, 17, 269-274.	0.8	11
57	Calcitoninâ€™Ultimobranchial Hormone. , 1968, , 306-321.		11
58	Pulmonary fibrosis in dyskeratosis congenita: report of 2 cases. Human Pathology, 2015, 46, 147-152.	1.1	10
59	The PD 20 but not the PC 20 in a methacholine challenge test is device independent. Annals of Allergy, Asthma and Immunology, 2017, 118, 508-509.	0.5	10
60	Methacholine Challenge: Comparison of Airway Responsiveness Produced by a Vibrating Mesh Nebulizer Versus a Jet Nebulizer. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2018, 31, 88-93.	0.7	10
61	Methacholine Challenge Methods. Chest, 2008, 134, 678-680.	0.4	9
62	Salbutamol tolerance to bronchoprotection: course of onset. Annals of Allergy, Asthma and Immunology, 2012, 109, 454-457.	0.5	9
63	Importance of dosimeter calibration method on nebulizer output. Annals of Allergy, Asthma and Immunology, 2005, 94, 45-47.	0.5	8
64	Development of a Methacholine Challenge Method to Minimize Methacholine Waste. Chest, 2003, 124, 1522-1525.	0.4	7
65	Methacholine Challenge. PD20versus PC20. Annals of the American Thoracic Society, 2015, 12, 291-292.	1.5	7
66	Airway hyperresponsiveness and chronic obstructive pulmonary disease outcomes. Journal of Allergy and Clinical Immunology, 2016, 138, 1580-1581.	1.5	7
67	Bronchial Challenge Testing. , 2014, , 1042-1055.		7
68	Deep inhalation bronchoprotection in asthma: Correlation with airway responsiveness. Journal of Allergy and Clinical Immunology, 2006, 117, 951-952.	1.5	6
69	METHACHOLINE PC20: 1-POINT FORMULA. Annals of Allergy, Asthma and Immunology, 2007, 98, 498-499.	0.5	6
70	Allergen-Induced Asthma. Canadian Respiratory Journal, 2014, 21, 279-282.	0.8	6
71	Allergen inhalation challenge, refractoriness and the effects of ibuprofen. Allergy, Asthma and Clinical Immunology, 2016, 12, 24.	0.9	6
72	Comparison of methacholine and mannitol challenges: importance of method of methacholine inhalation. Allergy, Asthma and Clinical Immunology, 2020, 16, 14.	0.9	6

#	ARTICLE	IF	CITATIONS
73	OUTPATIENT ASTHMA MANAGEMENT. <i>Medical Clinics of North America</i> , 1996, 80, 701-718.	1.1	5
74	Lack of Tachyphylaxis to Methacholine at 24 h. <i>Chest</i> , 2005, 128, 1248-1251.	0.4	5
75	Histamine and methacholine challenge cut points. <i>Annals of Allergy, Asthma and Immunology</i> , 2010, 104, 450-451.	0.5	5
76	Low levels of fractional exhaled nitric oxide and deep inhalation bronchoprotection are associated with mannitol non-responsiveness in asthma. <i>Respiratory Medicine</i> , 2014, 108, 859-864.	1.3	5
77	Direct bronchoprovocation test methods: history 1945â€“2018. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 279-289.	1.0	5
78	Overreliance on Bronchodilators as a Risk Factor for Life-Threatening Asthma. <i>Canadian Respiratory Journal</i> , 1995, 2, 34-39.	0.8	4
79	As-Needed Inhaled β_2 -Adrenoceptor Agonists in Moderate-to-Severe Asthma. <i>Treatments in Respiratory Medicine</i> , 2005, 4, 169-174.	1.4	4
80	Methacholine Challenge. <i>Clinical Pulmonary Medicine</i> , 2007, 14, 1-6.	0.3	4
81	Respiratory Duty Cycles in Individuals With and Without Airway Hyperresponsiveness. <i>Chest</i> , 2020, 157, 356-362.	0.4	4
82	The effect of deep inhalation on mannitol responsiveness. <i>Clinical and Experimental Allergy</i> , 2020, 50, 308-314.	1.4	4
83	Determination of Post-Salbutamol Methacholine Dose Shift. <i>Chest</i> , 1996, 110, 579-580.	0.4	3
84	At Least Three FEV ₁ Blows Are Required at Each Time Point During the Assessment of Bronchial Hyperresponsiveness. <i>Chest</i> , 2005, 128, 470.	0.4	3
85	Effect of ingested H ₁ antihistamines on methacholine challenge. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 579-580.	1.5	3
86	Bronchoprotective effect of vilanterol against methacholine-induced bronchoconstriction in mild asthmatics. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 328-332.	0.5	3
87	Short-term effect of once-daily fluticasone furoate on methacholine-induced bronchoconstriction in mild asthmatics. <i>Respiratory Medicine</i> , 2019, 156, 53-57.	1.3	3
88	Methacholine Challenge Testing in the Diagnosis of Asthma. <i>Chest</i> , 2020, 158, 433-434.	0.4	3
89	Characterizing the early and late asthmatic responses in the allergen inhalation challenge. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 600-602.	0.5	3
90	Atopy risk among school-aged children in relation to early exposures to a farm environment: A systematic review. <i>Respiratory Medicine</i> , 2021, 186, 106378.	1.3	3

#	ARTICLE	IF	CITATIONS
91	Frederick E. "Freddy" Hargreave, MB ChB, MD. Annals of Allergy, Asthma and Immunology, 2016, 116, 271-273.	0.5	2
92	Use of a vibrating mesh nebulizer for allergen challenge. Allergy, Asthma and Clinical Immunology, 2019, 15, 73.	0.9	2
93	Acute salbutamol bronchoprotection against methacholine. Annals of Allergy, Asthma and Immunology, 2020, 124, 633-634.	0.5	2
94	Bronchial Challenge Testing. , 2009, , 1295-1308.		2
95	Asthma and Therapeutics: Recombinant Therapies in Asthma. Allergy, Asthma and Clinical Immunology, 2005, 1, 34.	0.9	1
96	Comparison of doubling and quadrupling methacholine concentration regimens using the tidal volume method. Annals of Allergy, Asthma and Immunology, 2011, 106, 74-76.	0.5	1
97	Diversity of methacholine dose-response curves among asymptomatic non-asthmatics. Respiratory Medicine, 2017, 132, 109-111.	1.3	1
98	Reversible bilateral phrenic nerve paralysis. Respiratory Medicine Case Reports, 2019, 28, 100953.	0.2	1
99	Obesity and airway hyper-responsiveness. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 112-116.	0.2	1
100	Within-tester repeatability and between-tester reproducibility of skin test endpoint titration. Annals of Allergy, Asthma and Immunology, 2019, 122, 220-222.	0.5	1
101	Direct and indirect bronchoprovocation tests in dose-response studies of inhaled corticosteroids: Past, present, and future directions. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 76, 1679-1692.	2.7	1
102	Assessment Of Ratio Of Peak Expiratory Flow Rate To Vital Capacity For Identifying Pulmonary Fibrosis. Clinical and Investigative Medicine, 2021, 44, E25-27.	0.3	1
103	Effect of daily tiotropium on allergen-induced early asthmatic responses and airway inflammation. Annals of Allergy, Asthma and Immunology, 2022, , .	0.5	1
104	Is the Result of Methacholine Challenge Accurate for Assessing the Bronchoprotective Effects of Long-Acting β_2 -Adrenergic Bronchodilators?-To the Editor. Chest, 1996, 110, 305-306.	0.4	0
105	Loss of Bronchoprotection With Salmeterol-To the Editor. Chest, 1996, 110, 306.	0.4	0
106	Protease Inhibitor Phenotype BsaskatoonM Is Not Associated with Emphysema " A 20-Year Follow-Up Study. Canadian Respiratory Journal, 1999, 6, 407-411.	0.8	0
107	Abbreviated Methacholine Challenge. Chest, 2002, 122, 753.	0.4	0
108	Value of the diluent step in methacholine challenge tests. Annals of Allergy, Asthma and Immunology, 2002, 89, 4-6.	0.5	0

#	ARTICLE	IF	CITATIONS
109	Magnitude of Bronchoprotection of Albuterol vs Methacholine. Chest, 2006, 130, 622-623.	0.4	0
110	Allergens. , 2009, , 443-455.		0
111	Characterization of the methacholine PC15. Annals of Allergy, Asthma and Immunology, 2011, 107, 371.	0.5	0
112	Deep inhalation bronchoprotection. Annals of Allergy, Asthma and Immunology, 2012, 109, 74-75.	0.5	0
113	An Uncommon Cause of Wheeze. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 616-617.	2.0	0
114	Respiratory Medicine in Saskatchewan: An Historical Perspective. Canadian Respiratory Journal, 2015, 22, e27-e32.	0.8	0
115	Comparability of methacholine challenge test results between two jet nebulizers. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 69-71.	0.2	0
116	Regular use effect of inhaled ipratropium bromide and methacholine responsiveness in well-controlled asthma. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, , 1-6.	0.2	0
117	Nasal and Bronchial Provocation Tests. , 2009, , 49-62.		0
118	Nasal and Bronchial Nonallergic Provocation Tests. , 2009, , 63-79.		0